Rossari Biotech Limited (BOM:543213)

Rossari Biotech Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Operating Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	1,492	1,364	1,307	1,073	976.74
Depreciation & Amortization	791.24	670.73	603.9	627.6	480.01
Other Amortization	-	-	-	1.71	0.54
Loss (Gain) From Sale of Assets	-195.49	0.69	-18.78	-2.83	-6.38
Loss (Gain) From Sale of Investments	-9.07	-18.98	-25.18	-2.71	-14.18
Loss (Gain) on Equity Investments	-19.01	-9.78	-1.75	-9.57	-15.54
Stock-Based Compensation	33.3	0.68	6.87	9.43	18.31
Provision & Write-off of Bad Debts	15.42	29.47	36.02	20.15	8.86
Other Operating Activities	80.71	67.61	93.06	77.54	-34.31
Change in Accounts Receivable	-1,349	-853.92	-1,126	-286.03	-425.28
Change in Inventory	-494.64	-727.54	-938.48	7.32	-481.85
Change in Accounts Payable	305.23	851.69	496.34	0.4	-213.34
Operating Cash Flow	650.68	1,374	432.55	1,516	293.58
Operating Cash Flow Growth	-52.66%	217.75%	-71.46%	416.24%	-38.54%

Investing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-2,647	-1,585	-1,313	-328.76	-382.25
Sale of Property, Plant & Equipment	241.74	0.21	54.94	16.85	19.11
Cash Acquisitions	-	-3.15	-177.33	-985.31	-3,475
Investment in Securities	231.18	-178.31	376.04	-534.37	799.57
Other Investing Activities	-21.01	-70.58	27.04	22.65	49.69
Investing Cash Flow	-2,195	-1,837	-1,032	-1,809	-2,989

Financing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Short-Term Debt Issued	2,083	272.46	434.8	205.85	-
Long-Term Debt Issued	313.07	934.79	-	449.16	-
Total Debt Issued	2,396	1,207	434.8	655.01	-
Short-Term Debt Repaid	-	-	-	-	-48.12
Long-Term Debt Repaid	-261.54	-416.09	-123.93	-	-
Total Debt Repaid	-261.54	-416.09	-123.93	-	-48.12
Net Debt Issued (Repaid)	2,134	791.16	310.87	655.01	-48.12
Issuance of Common Stock	8.33	50.67	38.45	42.12	3,015
Common Dividends Paid	-27.68	-27.65	-27.58	-27.53	-27.53
Other Financing Activities	-251.59	-165.17	-159.89	-61.05	-21.5
Financing Cash Flow	1,863	649.01	161.85	608.55	2,918

Net Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Foreign Exchange Rate Adjustments	-8.04	3.83	-2.54	2.02	-
Net Cash Flow	311.05	190.32	-440.28	317.21	222.69

Free Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	-1,996	-210.69	-880.28	1,187	-88.67
Free Cash Flow Growth	-	-	-	-	-
Free Cash Flow Margin	-8.33%	-1.01%	-4.81%	7.17%	-0.60%
Free Cash Flow Per Share	-36.02	-3.81	-15.91	21.44	-1.61
Levered Free Cash Flow	-2,392	-579.18	-1,288	1,088	-579.33
Unlevered Free Cash Flow	-2,213	-467.86	-1,167	1,227	-500.23

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash Interest Paid	251.59	165.17	159.89	61.05	21.5
Cash Income Tax Paid	687.58	592.04	538.75	477.77	501.24
Change in Working Capital	-1,539	-729.77	-1,568	-278.31	-1,120

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 18, 2026

Data Sources Report a data error